Loading
A phase 1/2 trial of Pembrolizumab and Bevacizumab in advanced solid tumours, run by Shionogi, now recruiting.
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05101070 by Shionogi, with 282 participants planned, started 2022-05-30 and due to reach its primary completion in 2028-05-31. Interventions recorded: S-531011, Pembrolizumab and Bevacizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/